Sierra Capital’s Amedisys AMED Stock Holding History

Sierra Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19	Closed	-$3K	–	729
2022 Q1	$3K	Hold	19	–	–	﹤0.01%	576
2021 Q4	$3K	Buy	+19	New	+$3.05K	﹤0.01%	571

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sierra Capital's AMED Position: Q2 2022 in Review

Sierra Capital sold out of Amedisys (AMED) in Q2 2022, closing a stake of 19 shares — an estimated $3K sold.

Sierra Capital first reported a position in AMED in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Sierra Capital reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Sierra Capital sold 19 Amedisys shares in Q2 2022, an estimated $3K.
Sierra Capital first reported a position in Amedisys in Q4 2021 and held it in 2 quarters.
Sierra Capital's Amedisys position peaked at $3K in Q1 2022.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Sierra Capital's 13F filing for Q2 2022, filed 4 Aug 2022.